Differential proteomics in the search for biomarkers of radiotherapy resistance

References

• Thoms J, Bristow RG. DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin. Radiat. Oncol.20(4), 217–222 (2010).
   PubMed Web of Science ®Google Scholar
• Ashwell S, Zabludoff S. DNA damage detection and repair pathways – recent advances with inhibitors of checkpoint kinases in cancer therapy. Clin. Cancer Res.14(13), 4032–4037 (2008).
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol.24(11), 1770–1783 (2006).
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer9(3), 153–166 (2009).
   PubMed Web of Science ®Google Scholar
• Skladanowski A, Bozko P, Sabisz M. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment. Chem. Rev.109(7), 2951–2973 (2009).
   PubMed Web of Science ®Google Scholar
• Cheng Q, Chen J. Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle9(3), 472–478 (2010).
   PubMed Web of Science ®Google Scholar
• Darzynkiewicz Z, Traganos F, Wlodkowic D. Impaired DNA damage response – an Achilles’ heel sensitizing cancer to chemotherapy and radiotherapy. Eur. J. Pharmacol.625(1–3), 143–150 (2009).
   PubMed Web of Science ®Google Scholar
• Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene29(46), 6085–6098 (2010).
   PubMed Web of Science ®Google Scholar
• Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr. Opin. Cell. Biol.21(2), 245–255 (2009).
   PubMed Web of Science ®Google Scholar
• Stolz A, Ertych N, Bastians H. Tumor suppressor CHK2: regulator of DNA damage response and mediator of chromosomal stability. Clin. Cancer Res.17(3), 401–405 (2011).
   PubMed Web of Science ®Google Scholar
• Motegi A, Murakawa Y, Takeda S. The vital link between the ubiquitin–proteasome pathway and DNA repair: impact on cancer therapy. Cancer Lett.283(1), 1–9 (2009).
   PubMedGoogle Scholar
• Smith L, Lind MJ, Drew PJ, Cawkwell L. The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy. Eur. J. Cancer43(16), 2330–2338 (2007).
   PubMed Web of Science ®Google Scholar
• Raffoul JJ, Banerjee S, Singh-Gupta V et al. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res.67(5), 2141–2149 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu Y, Hu J, Hu Y, Liu W. Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance. Cancer Treatment Rev.35(7), 590–596 (2009).
   PubMed Web of Science ®Google Scholar
• Barker CA, Powell SN. Enhancing radiotherapy through a greater understanding of homologous recombination. Semin. Radiat. Oncol.20(4), 267–273.e3 (2010).
   PubMed Web of Science ®Google Scholar
• Mukherjee B, Choy H, Nirodi C, Burma S. Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization. Semin. Radiat. Oncol.20(4), 250–257 (2010).
   PubMedGoogle Scholar
• Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK. Receptor signaling as a regulatory mechanism of DNA repair. Radiother. Oncol.92(3), 316–322 (2009).
   PubMed Web of Science ®Google Scholar
• Baumann M, Krause M, Dikomey E et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother. Oncol.83(3), 238–248 (2007).
   PubMed Web of Science ®Google Scholar
• Bussink J, van der Kogel AJ, Kaanders JHAM. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol.9(3), 288–296 (2008).
   PubMed Web of Science ®Google Scholar
• Zou L. DNA repair: a protein giant in its entirety. Nature467(7316), 667–668 (2010).
   Google Scholar
• O’Donovan PJ, Livingston DM. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis31(6), 961–967 (2010).
   PubMed Web of Science ®Google Scholar
• McEllin B, Camacho CV, Mukherjee B et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res.70(13), 5457–5464 (2010).
   PubMed Web of Science ®Google Scholar
• Powell C, Mikropoulos C, Kaye SB et al. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treatment Rev.36(7), 566–575 (2010).
   PubMed Web of Science ®Google Scholar
• Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin. Cancer Res.16(6), 1701–1708 (2010).
   PubMed Web of Science ®Google Scholar
• Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin. Cancer Res.13(24), 7254–7263 (2007).
   PubMed Web of Science ®Google Scholar
• Ward TH, Cummings J, Dean E et al. Biomarkers of apoptosis. Br. J. Cancer99(6), 841–846 (2008).
   PubMed Web of Science ®Google Scholar
• Mace PD, Shirley S, Day CL. Assembling the building blocks: structure and function of inhibitor of apoptosis proteins. Cell Death Differ.17(1), 46–53 (2009).
   Google Scholar
• Ploner C, Kofler R, Villunger A. Noxa: at the tip of the balance between life and death. Oncogene27(S1), S84–S92 (2008).
   PubMed Web of Science ®Google Scholar
• Fennell DA, Chacko A, Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene27(9), 1189–1197 (2008).
   PubMed Web of Science ®Google Scholar
• Katz D, Ito E, Liu F-F. On the path to seeking novel radiosensitizers. Int. J. Radiat. Oncol. Biol. Phys.73(4), 988–996 (2009).
   PubMed Web of Science ®Google Scholar
• Riesterer O, Milas L, Ang KK. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J. Clin. Oncol.25(26), 4075–4083 (2007).
   PubMed Web of Science ®Google Scholar
• Verheij M, Vens C, van Triest B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist. Updat.13(1–2), 29–43 (2010).
   PubMed Web of Science ®Google Scholar
• Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys.74(3), 673–688 (2009).
   PubMed Web of Science ®Google Scholar
• Schuurbiers O, Kaanders J, van der Heijden H, Dekhuijzen R, Oyen W, Bussink J. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J. Thorac. Oncol.4(6), 761–767 (2009).
   PubMed Web of Science ®Google Scholar
• Thariat J, Yildirim G, Mason KA, Garden AS, Milas L, Ang KK. Combination of radiotherapy with EGFR antagonists for head and neck carcinoma. Int. J. Clin. Oncol.12(2), 99–110 (2007).
   PubMedGoogle Scholar
• Hodgkinson VC, Eagle GL, Drew PJ, Lind MJ, Cawkwell L. Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. Cancer Lett.294(1), 13–24 (2010).
   PubMed Web of Science ®Google Scholar
• Hanash S, Taguchi A. The grand challenge to decipher the cancer proteome. Nat. Rev. Cancer10(9), 652–660 (2010).
   Google Scholar
• Penque D. Two-dimensional gel electrophoresis and mass spectrometry for biomarker discovery. Proteomics Clin. Appl.3(2), 155–172 (2009).
   PubMed Web of Science ®Google Scholar
• Wilm M. Quantitative proteomics in biological research. Proteomics9(20), 4590–4605 (2009).
   PubMed Web of Science ®Google Scholar
• Minden JS, Dowd SR, Meyer HE, Stühler K. Difference gel electrophoresis. Electrophoresis30(S1), S156–S161 (2009).
   PubMed Web of Science ®Google Scholar
• Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annu. Rev. Biomed. Eng.11(1), 49–79 (2009).
   PubMed Web of Science ®Google Scholar
• Pan S, Aebersold R, Chen R et al. Mass spectrometry based targeted protein quantification: methods and applications. J. Proteome Res.8(2), 787–797 (2008).
   Web of Science ®Google Scholar
• Brennan DJ, O’Connor DP, Rexhepaj E, Ponten F, Gallagher WM. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat. Rev. Cancer10(9), 605–617 (2010).
   PubMed Web of Science ®Google Scholar
• Keller BO, Sui J, Young AB, Whittal RM. Interferences and contaminants encountered in modern mass spectrometry. Analytica Chimica Acta627(1), 71–81 (2008).
   PubMed Web of Science ®Google Scholar
• Paulovich A, Whiteaker J, Hoofnagle A, Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin. Appl.2(10–11), 1386–1402 (2008).
   PubMed Web of Science ®Google Scholar
• Hodgkinson VC, ElFadl D, Drew PJ, Lind MJ, Cawkwell L. Repeatedly identified differentially expressed proteins (RIDEPs) from antibody microarray proteomic analysis. J. Proteomics74(5), 698–703 (2011).
   Google Scholar
• Petrak J, Ivanek R, Toman O et al. Déjà vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics8(9), 1744–1749 (2008).
   PubMed Web of Science ®Google Scholar
• Wang P, Bouwman FG, Mariman ECM. Generally detected proteins in comparative proteomics – a matter of cellular stress response? Proteomics9(11), 2955–2966 (2009).
   PubMed Web of Science ®Google Scholar
• Mariman EC. 2DE-proteomics meta-data indicate the existence of distinct cellular stress-responsive mechanisms. Expert Rev. Proteomics6(4), 337–339 (2009).
   PubMed Web of Science ®Google Scholar
• Mullenders J, Bernards R. Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene28(50), 4409–4420 (2009).
   PubMed Web of Science ®Google Scholar
• Allal AS, Kähne T, Reverdin AK, Lippert H, Schlegel W, Reymond MA. Radioresistance-related proteins in rectal cancer. Proteomics4(8), 2261–2269 (2004).
   Google Scholar
• Henness S, Davey MW, Harvie RM et al. Changes in gene expression associated with stable drug and radiation resistance in small cell lung cancer cells are similar to those caused by a single x-ray dose. Radiat. Res.161(5), 495–503 (2004).
   PubMedGoogle Scholar
• Wang T, Tamae D, LeBon T, Shively JE, Yen Y, Li JJ. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res.65(22), 10338–10346 (2005).
   PubMedGoogle Scholar
• Skvortsova I, Skvortsov S, Stasyk T et al. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics8(21), 4521–4533 (2008).
   Google Scholar
• Smith L, Qutob O, Watson M et al. Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? Neoplasia11(11), 1194–1207 (2009).
   PubMed Web of Science ®Google Scholar
• Elfadl D, Hodgkinson VC, Long ED et al. A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer. Breast DOI:10.1016/j.breast.2011.02.017 (2011) (Epub ahead of print).
   Google Scholar
• Feng X-P, Yi H, Li M-Y et al. Identification of biomarkers for predicting nasopharyngeal carcinoma response to radiotherapy by proteomics. Cancer Res.70(9), 3450–3462 (2010).
   PubMed Web of Science ®Google Scholar
• Lin TY, Chang JT, Wang HM et al. Proteomics of the radioresistant phenotype in head-and-neck cancer: Gp96 as a novel prediction marker and sensitizing target for radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.78(1), 246–256 (2010).
   Google Scholar
• Chang JT, Chan SH, Lin CY et al. Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol. Cancer Ther.6(8), 2271–2279 (2007).
   PubMed Web of Science ®Google Scholar
• Kim JS, Chang JW, Yun HS et al. Chloride intracellular channel 1 identified using proteomic analysis plays an important role in the radiosensitivity of HEp-2 cells via reactive oxygen species production. Proteomics10(14), 2589–2604 (2010).
   PubMedGoogle Scholar
• Nix P, Greenman J, Cawkwell L, Stafford N. Defining the criteria for radioresistant laryngeal cancer. Clin. Otolaryngol. Allied Sci.29(6), 705–708 (2004).
   Google Scholar
• Nix P, Cawkwell L, Patmore H, Greenman J, Stafford N. Bcl-2 expression predicts radiotherapy failure in laryngeal cancer. Br. J. Cancer92(12), 2185–2189 (2005).
   PubMed Web of Science ®Google Scholar
• Vlashi E, Kim K, Lagadec C et al.In vivo imaging, tracking, and targeting of cancer stem cells. J. Natl Cancer Inst.101(5), 350–359 (2009).
   PubMed Web of Science ®Google Scholar
• Vlashi E, McBride WH, Pajonk F. Radiation responses of cancer stem cells. J. Cell. Biochem.108(2), 339–342 (2009).
   PubMed Web of Science ®Google Scholar
• Lagadec C, Vlashi E, Della Donna L et al. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res.12(1), R13 (2010).
   PubMed Web of Science ®Google Scholar